|
PRODUCT
DESCRIPTION
Oxford BioMedica’s 5T4 technology and intellectual property
include monoclonal antibodies that bind to the 5T4 antigen. Wyeth
is developing a targeted antibody therapy for the treatment
of cancer using a humanised version of anti-5T4 antibody linked
to a cytotoxic molecule, calicheamicin. The product is a ‘magic
bullet’ approach, which is designed to deliver the conjugate
directly and specifically to tumour cells, sparing healthy cells.
INDICATION
A wide range of cancers.
MARKET
The product could in principle be used to treat a wide range of
cancers and could therefore command a substantial market.
TECHNICAL
DESIGN
Humanised anti-5T4 antibody conjugated to a cytotoxic molecule,
calicheamicin.
CLINICAL
STATUS
- Wyeth is conducting further preclinical studies
- Preparations for clinical development are ongoing
PARTNERS/FUNDING
Wyeth
Website by College Hill - Life Sciences |
